Načítá se...
Immunotherapy for extensive stage small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy. Until recently the standard of care for newly diagnosed patients with extensive-stage disease was chemotherapy consisting of etoposide plus a platinum (EP). The median overall survival (OS) was only about 10 months with this systemic therapy...
Uloženo v:
| Vydáno v: | J Thorac Dis |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656428/ https://ncbi.nlm.nih.gov/pubmed/33209460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.01.37 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|